Galapagos $425 million private placement of shares

13/1/2016

Private placement of shares

Value:

$ 425 million

Status:

Completed

Date:

13/1/2016

Overview:

Pharmaceutical company Galapagos has privately placed $425 million of equity for US pharmaceutical group Gilead Sciences.
The offering is in connection with a global partnership between the two to develop a treatment for rheumatoid arthritis.
Also attached to the partnership is a $300 million license fee to be paid by Galapagos.

Kurt Stumpo - Journalist

Jurisdictions:

United States
Belgium

Deal type:

Private placement of shares

Practice area:

Capital markets : Equity

Industry sector:

Pharmaceuticals and life sciences

Firms:

Argo

Party: Galapogos (Issuer)

Lawyer: Nico Goossens

Eubelius

Party: Galapoggos (Issuer)

Goodwin Procter

Party: Gilead Sciences (Buyer)

Lawyer: Christopher Denn

Skadden Arps Slate Meagher & Flom

Party: Gilead Sciences (Buyer)

Lawyer: Graham Robinson

Related deals